Trevi Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Trevi Therapeutics, Inc. (TRVI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 337.65 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 6.46K shares.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 331.19K shares, a 394.25% increase year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 66.33K shares, a 22.38% decline year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 568.69K shares.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 690.87K shares, a 27.24% increase from fiscal 2024.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 542.96K shares, a 70.70% increase from fiscal 2023.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 318.07K shares, a 494.39% increase from fiscal 2022.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 53.51K shares, a 87.98% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 6.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 337.65K shares 10-Q · filed 2026-08-06 | 403.99K shares derived: sum of 3 quarters · filed 2026-08-06 | 972.68K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 331.19K shares 10-Q · filed 2026-05-05 | 397.52K shares derived: sum of 2 quarters · filed 2026-05-05 | 966.22K shares derived: sum of 3 quarters · filed 2026-05-05 | 955.05K shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 66.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 635.03K shares derived: sum of 2 quarters · filed 2026-03-17 | 623.86K shares derived: sum of 3 quarters · filed 2026-03-17 | 690.87K shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 568.69K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 557.53K shares derived: sum of 2 quarters · filed 2025-11-13 | 624.53K shares 10-Q · filed 2025-11-13 | 709.99K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | -11.17K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 55.84K shares 10-Q · filed 2025-08-07 | 141.30K shares derived: sum of 3 quarters · filed 2025-08-07 | |
| 2025-03-31 | 67.01K shares 10-Q · filed 2025-05-08 | 152.47K shares derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2024-12-31 | 85.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 542.96K shares 10-K · filed 2025-03-18 | ||
| 2024-09-30 | 457.50K shares 10-Q · filed 2024-11-06 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | 35.00K shares derived: sum of 2 quarters · filed 2024-03-20 | 35.00K shares derived: sum of 3 quarters · filed 2024-03-20 | 318.07K shares 10-K · filed 2024-03-20 |
| 2023-09-30 | 35.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 35.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 318.07K shares 10-Q · filed 2023-11-09 | 319.07K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 283.07K shares 10-Q · filed 2023-08-10 | 284.07K shares derived: sum of 3 quarters · filed 2023-08-10 | 295.36K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 283.07K shares 10-Q · filed 2023-05-11 | 284.07K shares derived: sum of 2 quarters · filed 2023-05-11 | 295.36K shares derived: sum of 3 quarters · filed 2023-05-11 | 333.96K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 1.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 12.29K shares derived: sum of 2 quarters · filed 2023-03-16 | 50.88K shares derived: sum of 3 quarters · filed 2023-03-16 | 53.51K shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 11.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 49.88K shares derived: sum of 2 quarters · filed 2022-11-10 | 52.51K shares 10-Q · filed 2022-11-10 | 77.39K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 38.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 41.22K shares 10-Q · filed 2022-08-11 | 66.10K shares derived: sum of 3 quarters · filed 2022-08-11 | 154.52K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 2.63K shares 10-Q · filed 2022-05-12 | 27.51K shares derived: sum of 2 quarters · filed 2022-05-12 | 115.92K shares derived: sum of 3 quarters · filed 2022-05-12 | |
| 2021-12-31 | 24.88K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 113.29K shares derived: sum of 2 quarters · filed 2022-03-17 | 445.12K shares 10-K · filed 2022-03-17 | |
| 2021-09-30 | 88.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 420.24K shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 331.82K shares 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | 151.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 151.62K shares derived: sum of 2 quarters · filed 2021-03-25 | 163.46K shares 10-K · filed 2021-03-25 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 11.84K shares 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | 11.84K shares 10-Q · filed 2020-08-13 | |||
| 2019-12-31 | 23.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | 23.68K shares derived: sum of 2 quarters · filed 2020-11-12 | 49.23K shares derived: sum of 3 quarters · filed 2020-11-12 | 59.43K shares 10-K · filed 2020-03-16 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 25.55K shares derived: sum of 2 quarters · filed 2020-11-12 | 35.74K shares 10-Q · filed 2020-11-12 | |
| 2019-06-30 | 25.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | 35.74K shares 10-Q · filed 2019-08-12 | ||
| 2019-03-31 | 10.20K shares 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |